News

News
Share this article
29 March 2018

Memorandum of Understanding between REDEFAR and ELF strengthens European connections

Prof Mabel Loza, coordinator of REDEFAR, the Spanish Network of Excellence in Drug Discovery, and the European Lead Factory executives Dr Dimitrios Tzalis and Dr Ton Rijnders have signed a Memorandum of Understanding for collaboration in future initiatives.

News
Share this article
29 March 2018

Chemistry partner EDELRIS praises collaboration within ELF

EDELRIS, a medicinal chemistry company, shares several LinkedIn posts explaining the key factors in the European Lead Factory that make their work possible. In their second post, EDELRIS tells more about their collaboration with the academic groups: 

News
Share this article
20 March 2018

Extraordinary hit compounds with API-like properties

At the end of 2017, Prof Reuven Stein received an extraordinary Qualified Hit List from the European Lead Factory. His research group studies the tumour microenvironment (TME) and has discovered a protein that plays an essential role in tumour progression. With the promising ELF compounds, they hope to develop new treatments for cancers such as glioma and melanoma.

News
Share this article
14 March 2018

ELF collaboration brings French biotech CELLIPSE one step closer to cancer treatment

After receiving its Qualified Hit List last year, the biotech company CELLIPSE has been successfully working together with the European Lead Factory (ELF) on their Improved Hit List.

News
Share this article
02 March 2018

Pharma Focus Asia interviews Ton Rijnders about results and successes of ELF

In their latest newsletter, Pharma Focus Asia incorporated an interview with Ton Rijnders, Head of Screening at the European Lead Factory. They were curious about the results of the European Lead Factory, but also about the success factors, learnings and the future of ELF. 

News
Share this article
27 February 2018

European Commission: ‘ELF is leading the way to discovering new medicines’

Under the topic “Success Stories”, the European Commission recognises the impact and potential of the European Lead Factory. The Directorate-General Research and Innovation highlighted that ‘researchers working on any human disease can call on a great resource to develop new drugs.’ 

News
Share this article
23 February 2018

European Lead Factory wins Multiparty Collaboration award

On Thursday 22 February, the European Lead Factory (ELF) won the Multiparty Collaboration award at the Scottish Knowledge Exchange Awards ceremony 2018. This reward, organised by Interface, recognises and rewards the impacts achieved through collaborative academic and business partnerships. The ELF collaboration comprises 30 public and private partners from across Europe, including large pharmaceutical companies, SMEs, CROs and academic institutions.

News
Share this article
22 February 2018

ELF shows how it grows a portfolio for the future

The European Lead Factory has been continuously recruiting high quality target programmes over the past years. With a clear infographic, the European Lead Factory makes the process of growing its portfolio visible.

News
Share this article
20 February 2018

ELF use of the “hot” technique MST

The European Lead Factory (ELF) scientists are not shy of applying new techniques to deliver the best possible results. A recent perspective, published in SLAS Discovery, describes how getting hot (or not) can help in the triaging of primary HTS hits.

News
Share this article
06 February 2018

PhD thesis enhanced with ELF collaboration and compounds

On 30 January 2018, Stefan Baumeister defended his dissertation ‘Investigation of the properties of Acyl Protein Thioesterases and their role in Ras depalmitoylation’ at the Max Planck Institute of Molecular Physiology (MPI) in Dortmund. His thesis describes structural determinants for selectivity between two closely related enzymes. Specific inhibitors could be optimized thanks to compounds derived from Dr. Sonja Siever’s ELF programme. The new insights can prove important for understanding the role of these enzymes in the course of cancer. 

Pages